Nothing Special   »   [go: up one dir, main page]

PE20120620A1 - Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas - Google Patents

Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas

Info

Publication number
PE20120620A1
PE20120620A1 PE2011001768A PE2011001768A PE20120620A1 PE 20120620 A1 PE20120620 A1 PE 20120620A1 PE 2011001768 A PE2011001768 A PE 2011001768A PE 2011001768 A PE2011001768 A PE 2011001768A PE 20120620 A1 PE20120620 A1 PE 20120620A1
Authority
PE
Peru
Prior art keywords
dihydropirazolones
propil
hif
inhibitors
formula
Prior art date
Application number
PE2011001768A
Other languages
English (en)
Inventor
Kai Thede
Ingo Flamme
Felix Oehme
Jens-Kerim Erguden
Friederike Stoll
Joachim Schuhmacher
Hanno Wild
Peter Kolkhof
Hartmut Beck
Jorg Keldenich
Metin Akbaba
Mario Jeske
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20120620A1 publication Critical patent/PE20120620A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE DIHIDROPIRAZOLONAS DE FORMULA (I) DONDE R1 ES UN COMPUESTO DE FORMULA (i), (ii), ENTRE OTROS, DONDE R4 ES H, F, CN, ALQUILO(C1-C4), TRIFLUOROMETILO, ENTRE OTROS; R2 ES UN COMPUESTO HETEROARILO DE FORMULA (iii) O (iv) EN DONDE G ES CR6 O N, DONDE R6 ES H, CLORO, HIDROXI, ALCOXI(C1-C6), ENTRE OTROS; J ES S; R3 ES H. SON COMPUESTOS PREFERIDOS: 2-[5-(HIDROXIMETILO)PIRIDIN-2-IL]-4-[4-(TRIFLUOROMETILO)-1H-IMIDAZOL-1-IL]-1,2-DIHIDRO-3H-PIRAZOL-3-ONA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DEL FACTOR DE TRANSCRIPCION INDUCIBLE POR HIPOXIA PROPIL-4-HIDROXILASA (HIF-PROPIL-4-HIDROXILASA) SIENDO UTILES EN EL TRATAMIENTO DE INSUFICIENCIA CARDIACA, ANGINA DE PECHO, ANEMIA, GLAUCOMA
PE2011001768A 2006-10-26 2007-10-25 Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas PE20120620A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006050516A DE102006050516A1 (de) 2006-10-26 2006-10-26 Substituierte Dihydropyrazolone und ihre Verwendung

Publications (1)

Publication Number Publication Date
PE20120620A1 true PE20120620A1 (es) 2012-05-27

Family

ID=38734870

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2012000031A PE20120635A1 (es) 2006-10-26 2007-10-25 Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE2007001451A PE20080895A1 (es) 2006-10-26 2007-10-25 Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE2011001768A PE20120620A1 (es) 2006-10-26 2007-10-25 Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2012000031A PE20120635A1 (es) 2006-10-26 2007-10-25 Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE2007001451A PE20080895A1 (es) 2006-10-26 2007-10-25 Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas

Country Status (41)

Country Link
US (5) US8389520B2 (es)
EP (3) EP2084151B1 (es)
JP (2) JP5247712B2 (es)
KR (1) KR101455879B1 (es)
CN (2) CN101631785B (es)
AR (1) AR063392A1 (es)
AU (1) AU2007328052B2 (es)
BR (1) BRPI0717367B8 (es)
CA (1) CA2667382C (es)
CO (1) CO6170359A2 (es)
CR (2) CR10750A (es)
CU (2) CU23743B7 (es)
CY (1) CY1114272T1 (es)
DE (1) DE102006050516A1 (es)
DK (2) DK2546253T3 (es)
ES (3) ES2534872T3 (es)
GT (1) GT200900095A (es)
HK (2) HK1140478A1 (es)
HN (1) HN2009000784A (es)
HR (2) HRP20130779T1 (es)
IL (2) IL198289A (es)
MA (1) MA30914B1 (es)
MX (1) MX2009004324A (es)
MY (1) MY169564A (es)
NO (1) NO343308B1 (es)
NZ (2) NZ596583A (es)
PE (3) PE20120635A1 (es)
PH (1) PH12013500578A1 (es)
PL (2) PL2546253T3 (es)
PT (2) PT2084151E (es)
RS (1) RS52924B (es)
RU (2) RU2469031C2 (es)
SG (1) SG176421A1 (es)
SI (1) SI2084151T1 (es)
SV (1) SV2009003236A (es)
TN (1) TN2009000132A1 (es)
TW (3) TWI437991B (es)
UA (1) UA98125C2 (es)
UY (1) UY30663A1 (es)
WO (1) WO2008067871A1 (es)
ZA (1) ZA200902705B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
DE102008020113A1 (de) * 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
DE102006050515A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
DE102006050513A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substitiuierte Dihydropyrazolone und ihre Verwendung
PT2294066E (pt) 2008-04-28 2014-11-21 Janssen Pharmaceutica Nv Benzoimidazoles como inibidores da prolil-hidroxilase
FR2949466A1 (fr) * 2009-08-28 2011-03-04 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique comme activateurs de hif
PT2382205E (pt) * 2008-12-29 2014-07-28 Sanofi Sa Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, sua preparação e sua aplicação terapêutica como activadores de hif
FR2940651B1 (fr) * 2008-12-29 2013-05-03 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique comme activateurs de hif
DK2382215T3 (da) 2008-12-29 2014-10-27 Sanofi Sa Derivater af 2-pyridin-2-yl-pyrazol-3(2h)-on, fremstilling og terapeutisk anvendelse heraf
IT1393337B1 (it) 2009-03-06 2012-04-20 Italiana Sint Spa Sintesi di (4as, 7as)-ottaidro-1h-pirrolo[3,4-b]piridina
DE102010044131A1 (de) * 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
JP6122862B2 (ja) 2011-10-25 2017-04-26 ヤンセン ファーマシューティカ エヌ．ベー． １−（５，６−ジクロロ−１ｈ−ベンゾ［ｄ］イミダゾール−２−イル）−１ｈ−ピラゾール−４−カルボン酸のメグルミン塩製剤
EP2628722A1 (en) 2012-02-16 2013-08-21 Bayer CropScience AG CF3O-containing enaminoketones and their utilization for the preparation of CF3O-containing pyrazoles
KR20140138208A (ko) * 2012-03-30 2014-12-03 다이이찌 산쿄 가부시키가이샤 4-알카노일아미노-3-피라졸론 유도체
AU2013258107B2 (en) * 2012-05-08 2017-06-22 Bayer Pharma Aktiengesellschaft Method for the preparation of triazole compounds
CN104334565A (zh) 2012-05-29 2015-02-04 莫门蒂夫性能材料有限责任公司 异氰酸基硅烷的制备
RS56974B1 (sr) * 2013-03-29 2018-05-31 Takeda Pharmaceuticals Co Derivati 6-(5-hidroksi-1h-pirazol-1-il)nikotinamida i njihova primena kao inhibitori phd
US9827198B2 (en) 2013-10-17 2017-11-28 Bayer Pharma Aktiengesellschaft Pharmaceutical dosage forms comprising sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate
CA2959688C (en) 2014-09-02 2024-02-27 Sunshine Lake Pharma Co., Ltd. Quinolone compounds and their use to treat diseases related to hypoxia inducible factor and/or erythropoietin
CN107778262A (zh) * 2016-08-24 2018-03-09 尹玉新 1,5‑双取代四氮唑类化合物及其制备方法和应用
CN109694380B (zh) * 2017-10-23 2022-09-27 中国医药研究开发中心有限公司 二氢吡唑啉酮类化合物及其制备方法和医药用途
CN111825690B (zh) * 2019-04-17 2022-09-27 中国医药研究开发中心有限公司 一种phd抑制剂的新晶型及其制备方法
US11579118B2 (en) 2019-06-03 2023-02-14 Tdw Delaware, Inc. Single point contact triaxial sensor head for an inline inspection tool
US10702525B1 (en) 2019-09-04 2020-07-07 United Arab Emirates University Pyrimidine derivatives as anti-diabetic agents
EP4103281A1 (en) * 2020-02-11 2022-12-21 Acurastem Inc. Pikfyve kinase inhibitors
BR112022016400A2 (pt) 2020-02-18 2022-10-25 Bayer Ag Compostos inovadores de heteroaril-triazol como pesticidas
CN115605467A (zh) * 2020-03-20 2023-01-13 阿克比治疗有限公司（Us） Phd抑制剂化合物、组合物和其用途
EP3888684A1 (en) 2020-03-31 2021-10-06 Bayer Animal Health GmbH Composition having improved voluntary acceptance
TW202200134A (zh) 2020-04-20 2022-01-01 美商阿克比治療有限公司 治療病毒感染、器官損傷及相關症狀之方法
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
WO2022251563A1 (en) 2021-05-27 2022-12-01 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
CN116120340B (zh) * 2021-11-15 2023-10-31 艾立康药业股份有限公司 一种吡啶并噁嗪类化合物及其制备方法、组合物和用途
GB202301059D0 (en) 2023-01-25 2023-03-08 Univ Oxford Innovation Ltd PHD inhibitors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE424016C (de) 1923-05-20 1926-01-14 Allg Vergasungs Ges M B H Fa Schachtofen mit Schwelaufsatz zur Vergasung und Verschwelung bituminoeser Stoffe
FR1519069A (fr) 1966-04-13 1968-03-29 Geigy Ag J R Dérivés du sulfanilamide et leur préparation
GR63123B (en) 1975-12-11 1979-09-11 Lilly Co Eli Preparation process of novel 1,4-diphenyl-3-pyrazolin-5-ones
US4075003A (en) 1975-12-11 1978-02-21 Eli Lilly And Company Novel herbicidal method utilizing 1,4-diphenyl-3-pyrazolin-5-ones
PL103509B1 (pl) 1976-09-20 1979-06-30 Lilly Co Eli Srodek chwastobojczy
US4663327A (en) 1984-05-23 1987-05-05 Bayer Aktiengesellschaft 1-heteroaryl-4-aryl-pyrazolin-5-ones
DE3443308A1 (de) * 1984-11-28 1986-05-28 Bayer Ag, 5090 Leverkusen 1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel
DE3527157A1 (de) 1985-07-30 1987-02-12 Bayer Ag 1-heteroaryl-4-aryl-pyrazol-derivate
DE4204919A1 (de) 1992-02-19 1993-08-26 Bayer Ag Verfahren zur herstellung von 2-chlor-5-alkylaminomethyl-pyridinen
DE4240168A1 (de) 1992-11-30 1994-06-01 Bayer Ag Cumarin-Derivate, Verfahren zu ihrer Herstellung und ihrer Verwendung
FR2725988B1 (fr) 1994-10-24 1997-01-24 Roussel Uclaf Nouveaux derives de pyrazolones et pyrazoles acides, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
JPH10306077A (ja) 1997-05-07 1998-11-17 Daiichi Rajio Isotope Kenkyusho:Kk ビピラゾール誘導体並びにこれを有効成分とする医薬および試薬
DE19909237A1 (de) 1999-03-03 2000-09-07 Merck Patent Gmbh Pyrazol-3-on-derivate
TR200401912T4 (tr) * 2000-03-20 2004-09-21 N-Gene Research Laboratories Inc. Propenkarboksilik asit amidoksim türevleri, bu türevlerin hazırlanması için işlem ve bu türevleri ihtiva eden farmasötik bileşimler
US6878729B2 (en) * 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
EP1404669A2 (en) 2001-05-16 2004-04-07 Vertex Pharmaceuticals Incorporated Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
AU2002359714B2 (en) 2001-12-18 2006-12-21 Merck Sharp & Dohme Corp. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
AU2003213673A1 (en) 2002-03-01 2003-09-16 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
WO2004087066A2 (en) 2003-03-27 2004-10-14 Emory University Hif-1 inhibitors
AU2004228057A1 (en) 2003-04-03 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
EP1626718A4 (en) 2003-05-01 2010-05-05 Panacea Pharmaceuticals Inc METHOD FOR THE TREATMENT OF ISCHEMIC ILLNESSES
AU2004275694B2 (en) * 2003-06-30 2008-03-06 Bizbiotech Co., Ltd. Compounds, compositions and methods
AT7634U1 (de) 2004-06-29 2005-06-27 Binder Co Ag Detektiervorrichtung und sortiervorrichtung
CA2614068A1 (en) 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
DE102008020113A1 (de) * 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
CN101171235B (zh) 2005-03-16 2011-03-02 安万特药物公司 作为中枢神经系统活性剂的联吡唑类
RU2007139255A (ru) * 2005-04-26 2009-06-10 Ньюросерч А/С (DK) Новые оксадиазольные производные и их медицинское применение
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
DE102006050516A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
DE102006050515A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
DE102006050513A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substitiuierte Dihydropyrazolone und ihre Verwendung
DE102010044131A1 (de) 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat

Also Published As

Publication number Publication date
JP5247712B2 (ja) 2013-07-24
BRPI0717367A2 (pt) 2013-10-22
US20120121727A1 (en) 2012-05-17
PE20080895A1 (es) 2008-09-05
JP5300813B2 (ja) 2013-09-25
TW201345526A (zh) 2013-11-16
ES2534872T3 (es) 2015-04-29
CU24056B1 (es) 2014-12-26
AU2007328052A1 (en) 2008-06-12
CA2667382A1 (en) 2008-06-12
KR101455879B1 (ko) 2014-11-03
AR063392A1 (es) 2009-01-28
PL2546253T3 (pl) 2015-08-31
IL198289A0 (en) 2010-02-17
US9168249B2 (en) 2015-10-27
PT2084151E (pt) 2013-07-18
PT2546253E (pt) 2015-05-07
NZ596583A (en) 2013-05-31
CN101631785A (zh) 2010-01-20
CO6170359A2 (es) 2010-06-18
ES2621787T3 (es) 2017-07-05
NO343308B1 (no) 2019-01-28
CR20140392A (es) 2014-09-16
WO2008067871A1 (de) 2008-06-12
DK2546253T3 (en) 2015-04-20
CU20090066A7 (es) 2011-09-21
US8389520B2 (en) 2013-03-05
EP2383269A3 (de) 2012-01-11
UA98125C2 (ru) 2012-04-25
KR20090074811A (ko) 2009-07-07
TWI561237B (en) 2016-12-11
BRPI0717367B1 (pt) 2020-09-08
DE102006050516A1 (de) 2008-04-30
CU20110119A7 (es) 2012-01-31
CU23743B7 (es) 2012-01-31
PL2084151T3 (pl) 2013-10-31
SG176421A1 (en) 2011-12-29
PH12013500578B1 (en) 2014-09-08
TWI437991B (zh) 2014-05-21
CN101631785B (zh) 2013-08-21
BRPI0717367B8 (pt) 2021-05-25
US20160229858A1 (en) 2016-08-11
ZA200902705B (en) 2010-06-30
EP2084151B1 (de) 2013-05-29
CY1114272T1 (el) 2016-08-31
US8653111B2 (en) 2014-02-18
EP2383269B1 (de) 2017-01-18
US20150148381A1 (en) 2015-05-28
DK2084151T3 (da) 2013-09-02
EP2084151A1 (de) 2009-08-05
HRP20150396T1 (hr) 2015-05-08
SI2084151T1 (sl) 2013-10-30
MA30914B1 (fr) 2009-11-02
NO20091655L (no) 2009-06-26
CN103342696A (zh) 2013-10-09
US20100305085A1 (en) 2010-12-02
EP2546253B1 (de) 2015-01-14
MX2009004324A (es) 2009-05-12
GT200900095A (es) 2011-10-12
CR10750A (es) 2009-09-16
HRP20130779T1 (hr) 2013-09-30
US20140031329A1 (en) 2014-01-30
TW201630605A (zh) 2016-09-01
EP2546253A1 (de) 2013-01-16
RU2009119431A (ru) 2010-12-10
SV2009003236A (es) 2010-01-19
ES2421454T3 (es) 2013-09-02
NZ576458A (en) 2011-12-22
RU2469031C2 (ru) 2012-12-10
EP2383269A2 (de) 2011-11-02
US8987261B2 (en) 2015-03-24
PE20120635A1 (es) 2012-05-20
TW200833330A (en) 2008-08-16
JP2010507602A (ja) 2010-03-11
IL221928A (en) 2015-10-29
RS52924B (en) 2014-02-28
RU2012134284A (ru) 2014-02-20
AU2007328052B2 (en) 2013-11-07
TN2009000132A1 (en) 2010-10-18
CA2667382C (en) 2014-12-23
HK1140478A1 (en) 2010-10-15
CN103342696B (zh) 2015-03-11
RU2611012C2 (ru) 2017-02-17
HN2009000784A (es) 2012-02-27
HK1190153A1 (en) 2014-06-27
PH12013500578A1 (en) 2014-09-08
IL198289A (en) 2015-03-31
MY169564A (en) 2019-04-22
UY30663A1 (es) 2008-05-31
JP2011006486A (ja) 2011-01-13

Similar Documents

Publication Publication Date Title
PE20120620A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20070136A1 (es) COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1
NO20083909L (no) Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere
PE20110136A1 (es) Compuestos organicos
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EA201001595A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20141361A1 (es) Compuesto heterociclico dihidroxi aromatico
PE20081596A1 (es) Derivados fluorinados de deferiprona
EA201001585A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
PE20142099A1 (es) Derivados de sulfonamida
NO20076479L (no) Nye oksadiazolderivater og anvendelse derav som positive allosteriske metabotropiske modulatorer av glutamatreseptorer
DE602007009420D1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
PE20090649A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
AR059249A1 (es) Compuesto amina trisustituido
PE20061357A1 (es) COMPUESTOS DERIVADOS DE AMINOSULFONILO COMO INHIBIDORES DE LA 11-ß-HSD-1
MA34916B1 (fr) Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques
PE20090437A1 (es) Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos
TW200732313A (en) Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
PE20140934A1 (es) Derivados de pirazol
NO20076478L (no) Substituerte oksadiazolderivater som positive allosteriske modulatorer av metabotrope glutamatreseptorer
PE20081393A1 (es) Derivados de quinolina como inhibidores de csf-1r
HK1146049A1 (en) Isoxazole derivatives as modulators of 11-beta-hydroxysteroid dehydrogenase type 1
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
PE20060589A1 (es) FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b

Legal Events

Date Code Title Description
FG Grant, registration